
June 24 (Reuters) - Actuate Therapeutics Inc ACTU.O:
ACTUATE THERAPEUTICS HIGHLIGHTS SIGNIFICANT AND SUSTAINED SURVIVAL BENEFIT IN KEY METASTATIC PANCREATIC CANCER PATIENT POPULATIONS IN PHASE 2 ELRAGLUSIB TRIAL
ACTUATE THERAPEUTICS INC - ELRAGLUSIB PLUS GNP SHOWS NEAR DOUBLING OF 1-YEAR OS